PERSPECTIVE article
Front. Oncol.
Sec. Neuro-Oncology and Neurosurgical Oncology
This article is part of the Research TopicNavigating the Landscape of IDH-Mutant Gliomas: Advances in Diagnosis, Therapeutic Management, and Long-Term MonitoringView all articles
The role of a multidisciplinary clinic for management of patients with IDH mutant gliomas
Provisionally accepted
- Northwestern University Feinberg School of Medicine, Chicago, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Introduction: Management of IDH-mutant lower-grade gliomas (IDHm LGGs) is complex, requiring careful balance between tumor control as well as neurocognitive function and quality of life. While multidisciplinary clinics improve outcomes in other cancers, no structured model exists for IDHm LGGs. Methods: We present a framework for a multidisciplinary clinic a dedicated to patients with IDHm LGGs. Discussion: IDHm LGGs, including WHO grade 2 astrocytomas and oligodendrogliomas, affect younger adults with median survivals exceeding a decade. Tumor related seizures are a significant source of distress for patients with IDHm LGGs, in addition to burden of disease. Treatment decisions such as surgery, medical therapy, and radiation, along with seizure management are highly individualized and benefit from coordinated, longitudinal care. A dedicated multidisciplinary LGG clinic integrates expertise across neurosurgery, neuro-oncology, epilepsy, and neuropsychology to optimize outcomes and patient experience to create a onco-functional balance. Conclusion: A multidisciplinary clinic dedicated to IDHm LGGs can provide a collaborative model for comprehensive, patient-centered care for a rare and complex disease which may be replicated at other brain tumor centers.
Keywords: IDH mutant glioma, Low grade glioma, multidisciplinary care, Quality of Life, tumoral epilepsy
Received: 21 Oct 2025; Accepted: 30 Nov 2025.
Copyright: © 2025 Dixit, Aucoin, Templer and Tate. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Karan Dixit
Lauren Aucoin
Jessica Templer
Matthew Tate
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.